Acromegaly-Pipeline Review, H1 2015

Acromegaly-Pipeline Review, H1 2015

  • Products Id :- GMDHC6720IDB
  • |
  • Pages: 91
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Acromegaly-Pipeline Review, H1 2015


Global Markets Direct's, 'Acromegaly-Pipeline Review, H1 2015', provides an overview of the Acromegaly's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Acromegaly, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acromegaly and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


The report provides a snapshot of the global therapeutic landscape of Acromegaly

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Acromegaly and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Acromegaly products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Acromegaly pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Acromegaly

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Acromegaly pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Read More

Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications


Table of Contents

Table of Contents 2

List of Tables 6

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Acromegaly Overview 9

Therapeutics Development 10

Pipeline Products for Acromegaly-Overview 10

Pipeline Products for Acromegaly-Comparative Analysis 11

Acromegaly-Therapeutics under Development by Companies 12

Acromegaly-Therapeutics under Investigation by Universities/Institutes 13

Acromegaly-Pipeline Products Glance 14

Late Stage Products 14

Clinical Stage Products 15

Early Stage Products 16

Acromegaly-Products under Development by Companies 17

Acromegaly-Products under Investigation by Universities/Institutes 19

Acromegaly-Companies Involved in Therapeutics Development 20

Aegis Therapeutics, LLC 20

Antisense Therapeutics Limited 21

Chiasma, Inc. 22

Crinetics Pharmaceuticals, Inc. 23

DexTech Medical AB 24

Foresee Pharmaceuticals, LLC 25

GP Pharm, S.A. 26

Ipsen S.A. 27

Isis Pharmaceuticals, Inc. 28

Italfarmaco S.p.A. 29

Novartis AG 30

Paladin Labs Inc. 31

Peptron, Inc. 32

Sompharmaceuticals S.A. 33

Acromegaly-Therapeutics Assessment 34

Assessment by Monotherapy Products 34

Assessment by Target 35

Assessment by Mechanism of Action 37

Assessment by Route of Administration 39

Assessment by Molecule Type 41

Drug Profiles 43

ATL-1103-Drug Profile 43

Product Description 43

Mechanism of Action 43

R&D Progress 43

BIM-23A758-Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

DG-3173-Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

FP-002-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

G-02113-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

ISIS-GHRLRx-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

ITF-2984-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

L-779976-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

octreotide-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

octreotide acetate-Drug Profile 54

Product Description 54

Mechanism of Action 54

R&D Progress 54

octreotide acetate-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

octreotide acetate LAR-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

octreotide acetate long acting-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

octreotide acetate SR-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

octreotide SR-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

pasireotide LAR-Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

pegvisomant-Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

Small Molecules to Activate Somatostatin Receptor Type 4 for Oncology, Genito Urinary System And Sex Hormones and Metabolic Disorders-Drug Profile 65

Product Description 65

Mechanism of Action 65

R&D Progress 65

Somadex-Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

SXN-101742-Drug Profile 67

Product Description 67

Mechanism of Action 67

R&D Progress 67

SXN-101959-Drug Profile 68

Product Description 68

Mechanism of Action 68

R&D Progress 68

Acromegaly-Recent Pipeline Updates 69

Acromegaly-Dormant Projects 79

Acromegaly-Discontinued Products 80

Acromegaly-Product Development Milestones 81

Featured News & Press Releases 81

Apr 16, 2015: ATL1103-New European Patent Application Allowance 81

Mar 06, 2015: ATL1103 Phase II Trial Data to be presented at ENDO 2015 81

Mar 05, 2015: ATL1103 Higher Dose Study to Support Phase III to Commence 82

Mar 05, 2015: Chiasma Announces New Data for Investigational Octreotide Capsules 82

Feb 09, 2015: Newly Published Phase III Study Results Show Positive Outcomes for Octreotide Capsules in People with Acromegaly 84

Jan 26, 2015: Glide Appoints Albany Molecular Research for Manufacture of Novel Octreotide Solid Dose Formulation Clinical Trial Product 85

Dec 16, 2014: Novartis gains FDA approval for Signifor LAR to treat patients with acromegaly, a rare and life-threatening hormonal disorder 86

Dec 09, 2014: Antisense Therapeutics Provides ATL-1103 Update 87

Oct 17, 2014: Antisense Therapeutics Provides Update On ATL1103 For Acromegaly 88

Sep 26, 2014: Novartis drug Signifor LAR recommended by CHMP for EU approval to treat patients with rare hormonal disorder acromegaly 88

Appendix 90

Methodology 90

Coverage 90

Secondary Research 90

Primary Research 90

Expert Panel Validation 90

Contact Us 90

Disclaimer 91

List of Tables

Number of Products under Development for Acromegaly, H1 2015 10

Number of Products under Development for Acromegaly-Comparative Analysis, H1 2015 11

Number of Products under Development by Companies, H1 2015 12

Number of Products under Investigation by Universities/Institutes, H1 2015 13

Comparative Analysis by Late Stage Development, H1 2015 14

Comparative Analysis by Clinical Stage Development, H1 2015 15

Comparative Analysis by Early Stage Development, H1 2015 16

Products under Development by Companies, H1 2015 17

Products under Development by Companies, H1 2015 (Contd..1) 18

Products under Investigation by Universities/Institutes, H1 2015 19

Acromegaly-Pipeline by Aegis Therapeutics, LLC, H1 2015 20

Acromegaly-Pipeline by Antisense Therapeutics Limited, H1 2015 21

Acromegaly-Pipeline by Chiasma, Inc., H1 2015 22

Acromegaly-Pipeline by Crinetics Pharmaceuticals, Inc., H1 2015 23

Acromegaly-Pipeline by DexTech Medical AB, H1 2015 24

Acromegaly-Pipeline by Foresee Pharmaceuticals, LLC, H1 2015 25

Acromegaly-Pipeline by GP Pharm, S.A., H1 2015 26

Acromegaly-Pipeline by Ipsen S.A., H1 2015 27

Acromegaly-Pipeline by Isis Pharmaceuticals, Inc., H1 2015 28

Acromegaly-Pipeline by Italfarmaco S.p.A., H1 2015 29

Acromegaly-Pipeline by Novartis AG, H1 2015 30

Acromegaly-Pipeline by Paladin Labs Inc., H1 2015 31

Acromegaly-Pipeline by Peptron, Inc., H1 2015 32

Acromegaly-Pipeline by Sompharmaceuticals S.A., H1 2015 33

Assessment by Monotherapy Products, H1 2015 34

Number of Products by Stage and Target, H1 2015 36

Number of Products by Stage and Mechanism of Action, H1 2015 38

Number of Products by Stage and Route of Administration, H1 2015 40

Number of Products by Stage and Molecule Type, H1 2015 42

Acromegaly Therapeutics-Recent Pipeline Updates, H1 2015 69

Acromegaly-Dormant Projects, H1 2015 79

Acromegaly-Discontinued Products, H1 2015 80

List of Figures

Number of Products under Development for Acromegaly, H1 2015 10

Number of Products under Development for Acromegaly-Comparative Analysis, H1 2015 11

Number of Products under Development by Companies, H1 2015 12

Comparative Analysis by Clinical Stage Development, H1 2015 15

Comparative Analysis by Early Stage Products, H1 2015 16

Assessment by Monotherapy Products, H1 2015 34

Number of Products by Top 10 Targets, H1 2015 35

Number of Products by Stage and Top 10 Targets, H1 2015 36

Number of Products by Top 10 Mechanism of Actions, H1 2015 37

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 38

Number of Products by Top 10 Routes of Administration, H1 2015 39

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 40

Number of Products by Top 10 Molecule Types, H1 2015 41

Number of Products by Stage and Top 10 Molecule Types, H1 2015 42

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@]

Aegis Therapeutics, LLC

Antisense Therapeutics Limited

Chiasma, Inc.

Crinetics Pharmaceuticals, Inc.

DexTech Medical AB

Foresee Pharmaceuticals, LLC

GP Pharm, S.A.

Ipsen S.A.

Isis Pharmaceuticals, Inc.

Italfarmaco S.p.A.

Novartis AG

Paladin Labs Inc.

Peptron, Inc.

Sompharmaceuticals S.A.

Acromegaly Therapeutic Products under Development, Key Players in Acromegaly Therapeutics, Acromegaly Pipeline Overview, Acromegaly Pipeline, Acromegaly Pipeline Assessment

select a license

Single User License
USD 2000 INR 136600
Site License
USD 4000 INR 273200
Corporate User License
USD 6000 INR 409800



Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India


Company Brochure

Engage with Us

sales [@]